Buprenorphine and naloxone co-administration in opiate-dependent patients stabilized on sublingual buprenorphine (original) (raw)
Clinical and pharmacological evaluation of buprenorphine and naloxone combinations: why the 4:1 ratio for treatment?
John Mendelson
Drug and Alcohol Dependence, 2003
View PDFchevron_right
Effects of buprenorphine/naloxone in opioid-dependent humans
Kenneth Stoller
Psychopharmacology, 2001
View PDFchevron_right
Buprenorphine and naloxone interactions in methadone maintenance patients
Steven Batki
Biological Psychiatry, 1997
View PDFchevron_right
Sublingual versus subcutaneous buprenorphine in opiate abusers
Rolley Johnson
Clinical pharmacology and therapeutics, 1989
View PDFchevron_right
Rapid induction onto sublingual buprenorphine after opioid overdose and successful linkage to treatment for opioid use disorder
Mark Greenwald
American Journal of Emergency Medicine, 2019
View PDFchevron_right
Safety of a Rapidly Dissolving Buprenorphine/Naloxone Sublingual Tablet (BNX-RDT) for Treatment of Opioid Dependence: A Multicenter, Open-label Extension Study
Michael Sumner
Journal of Addiction Medicine, 2017
View PDFchevron_right
A pilot study of buprenorphine - naloxone combination tablet (Suboxone®) in treatment of opioid dependence
Amy Gibson
Drug and Alcohol Review, 2004
View PDFchevron_right
Naltrexone and buprenorphine combination in the treatment of opioid dependence
Adnan Zaimovic
Journal of Psychopharmacology, 2006
View PDFchevron_right
Buprenorphine versus methadone maintenance for the treatment of opioid dependence
Lukas Pezawas
Addiction, 1999
View PDFchevron_right
Case Series: Limited Opioid Withdrawal With Use of Transdermal Buprenorphine to Bridge to Sublingual Buprenorphine in Hospitalized Patients
Tim H Guimond
American Journal on Addictions, 2019
View PDFchevron_right
The Clinical Use of Buprenorphine in Opioid Addiction Treatment: Benefits and Limitations
Ramona (Himayini) Sharma
View PDFchevron_right
Sublingual buprenorphine/naloxone for chronic pain in at-risk patients: Development and pilot test of a clinical protocol
Andrew Rosenblum
Journal of Opioid Management, 2012
View PDFchevron_right
National clinical guidelines and procedures for the use of buprenorphine in the treatment of heroin dependence
Nicholas Lintzeris, Robert Ali
Efficacy, Cost-Effectiveness and Implementation Guidelines, 2009
View PDFchevron_right
A pilot study of buprenorphine – naloxone combination tablet (Suboxone®) in treatment of opioid dependence
Amy Gibson
2009
View PDFchevron_right
Effects of a Higher-bioavailability Buprenorphine/Naloxone Sublingual Tablet Versus Buprenorphine/Naloxone Film for the Treatment of Opioid Dependence During Induction and Stabilization: A Multicenter, Randomized Trial
Michael Sumner
Clinical Therapeutics, 2015
View PDFchevron_right
Effects of buprenorphine sublingual tablet maintenance on opioid drug-seeking behavior by humans
Chris-Ellyn Johanson
Psychopharmacology, 2002
View PDFchevron_right
National Clinical Guidelines and Procedures for the Use of Buprenorphine in the Treatment of Opioid Dependence
Nicholas Lintzeris
2000
View PDFchevron_right
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers
Ziva D Cooper
Addiction, 2010
View PDFchevron_right
Pharmacokinetic and pharmaceutical properties of a novel buprenorphine/naloxone sublingual tablet for opioid substitution therapy versus conventional buprenorphine/naloxone sublingual tablet in healthy volunteers
Michael Sumner
European Journal of Pharmaceutical Sciences, 2018
View PDFchevron_right
Buprenorphine in the treatment of opioid dependence
Markus Gastpar, Eugen Davids
European Neuropsychopharmacology, 2004
View PDFchevron_right
Use of buprenorphine in the treatment of opiate addiction. I. Physiologic and behavioral effects during a rapid dose induction
Rolley Johnson, Edward Cone
Clinical pharmacology and therapeutics, 1989
View PDFchevron_right
Buprenorphine: a controlled clinical trial in the treatment of opioid dependence
Paolo Pani
Drug and Alcohol …, 2000
View PDFchevron_right
Assessment of differential doses of buprenorphine for long term pharmacotherapy among opiate dependent subjects
anju dhawan
Indian journal of physiology and pharmacology
View PDFchevron_right
Abuse liability of intravenous buprenorphine/naloxone and buprenorphine alone in buprenorphine-maintained intravenous heroin abusers: Abuse liability of buprenorphine/naloxone
Mudassir Mumtaz
Addiction, 2010
View PDFchevron_right
Buprenorphine for the treatment of opioid dependence
Anne Roussin
American Journal of Health-System Pharmacy, 2007
View PDFchevron_right
Pharmacokinetics of Sublingual Buprenorphine and Naloxone in Subjects with Mild to Severe Hepatic Impairment (Child-Pugh Classes A, B, and C), in Hepatitis C Virus-Seropositive Subjects, and in Healthy Volunteers
Azmi Nasser
Clinical Pharmacokinetics, 2015
View PDFchevron_right
Opioid Dependence Treatment, Including Buprenorphine/Naloxone
Kathy Boardman
The Annals of Pharmacotherapy, 2002
View PDFchevron_right
Buprenorphine Therapy for Opioid Use Disorder
Maria Mejia de Grubb
American family physician, 2018
View PDFchevron_right
Use of Buprenorphine in the Management of Opioid-Addicted Patients
Marla Oros
View PDFchevron_right
Safety and side-effects of buprenorphine in the clinical management of heroin addiction
Rolley Johnson
Drug and Alcohol Dependence, 1990
View PDFchevron_right
Intolerance of sublingual buprenorphine-naloxone during induction in a patient with end-stage liver disease: A case report
Michelle Geier
Mental Health Clinician
View PDFchevron_right